Mar 27, 2015 6:30 am EDT Atara Biotherapeutics, Inc. Appoints Eric Dobmeier, Chief Operating Officer of Seattle Genetics, Inc., to Its Board of Directors
Mar 19, 2015 6:30 am EDT Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV Lymphoma at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015
Mar 02, 2015 6:30 am EST FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease
Feb 26, 2015 4:05 pm EST Atara Biotherapeutics Announces Fourth Quarter and Full Year 2014 Operating Results
Feb 18, 2015 4:21 pm EST Atara Biotherapeutics Announces Closing of Underwritten Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares